Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Regulation of prefrontal cortex myelination by the microbiota.
Regenerative cellular therapies for neurologic diseases.
Kif1b is essential for mRNA localization in oligodendrocytes and development of myelinated axons.
Chronic cladribine administration increases amyloid Beta Peptide generation and plaque burden in mice.
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
Intas launches biosimilar version of Rituximab
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
European Commission Approves Genzyme’s Once-Daily, Oral Multiple Sclerosis Treatment Aubagio® (teriflunomide)
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?
Translating state-of-the-art spinal cord MRI techniques to clinical use: A systematic review of clinical studies utilizing DTI, MT, MWF, MRS, and fMRI.
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
A novel pH-sensitive interferon-β (INF-β) oral delivery system for application in multiple sclerosis.
Glatiramer acetate ameliorates experimental autoimmune neuritis.
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.
Visualizing Non-Gaussian Diffusion: Clinical Application of q-Space Imaging and Diffusional Kurtosis Imaging of the Brain and Spine.
Genzyme receives positive CHMP opinion in the European Union for once-daily, oral AUBAGIO® to treat relapsing-remitting multiple sclerosis
Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year Guidance
A full genome search in multiple sclerosis.
Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis.
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.

Pages